Literature DB >> 30699408

Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues.

Rajvilas A Narkhede1, Gunjan S Desai2, Pande P Prasad3, Prasad K Wagle4.   

Abstract

BACKGROUND: The incidence of pancreatic adenocarcinoma (PDAC) in patients with chronic pancreatitis (CP) is as high as 5%. It is a commonly encountered diagnostic challenge in patients with CP on long-term follow-up.
SUMMARY: This review consolidates the existing literature on assessment of PDAC in background of CP, its evaluation through the available investigations, surgical management, and prognostication. Recent change in symptomatology of an otherwise stable CP should raise a suspicion of malignancy. Endoscopic ultrasound (EUS) is more specific and sensitive in establishing the diagnosis of PDAC compared to cross-sectional imaging (computed tomography/magnetic resonance imaging). Intraoperative assessment with careful palpation coupled with careful clinical judgment helps in differentiating between an inflammatory mass and pancreatic cancer. Confirmation can be obtained with either preoperative EUS-guided fine needle cytology/core biopsy or intraoperative core biopsy under ultrasound guidance. However, despite complete evaluation with above options, 1-6% patients often show malignancy on final histopathological examination. Key Messages: Diagnosis of PDAC in CP needs a high index of suspicion. Cross-sectional imaging has poor negative predictive value. CA 19-9 with MUC5AC combination may become an ideal investigation. EUS with core biopsy/frozen section has a good sensitivity and specificity and low false negative results. Complete radical resection should be the aim to get long-term survival.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic pancreatitis; Pancreatic adenocarcinoma; Pancreatic cancer; Pancreatic head mass

Mesh:

Year:  2019        PMID: 30699408     DOI: 10.1159/000496507

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

1.  Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma.

Authors:  Sebastian Dwertmann Rico; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Daniel Perez; Jakob R Izbicki; Michael Neipp; Hamid Mofid; Thies Daniels; Christoph Isbert; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Andreas Marx; Till Krech
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

2.  LINC01232 Sponges Multiple miRNAs and Its Clinical Significance in Pancreatic Adenocarcinoma Diagnosis and Prognosis.

Authors:  Wenyan Du; Chengbin Lei; Yanzhen Wang; Yiwen Ding; Peng Tian
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

3.  MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples.

Authors:  Sebastian Dwertmann Rico; Moritz Mahnken; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Christina Möller-Koop; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Frank Jacobsen; Patrick Lebok; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Sarah Minner; Eike Burandt; Till Krech; Andreas H Marx
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

Review 4.  The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.

Authors:  Ashna A Kumar; Benjamin J Buckley; Marie Ranson
Journal:  Biomolecules       Date:  2022-01-18

Review 5.  Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer.

Authors:  Puvanesswaray Ramakrishnan; Wei Mee Loh; Subash C B Gopinath; Srinivasa Reddy Bonam; Ismail M Fareez; Rhanye Mac Guad; Maw Shin Sim; Yuan Seng Wu
Journal:  Acta Pharm Sin B       Date:  2019-11-14       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.